Roche acquires a Chinese obesity drug for 1.037 billion - Redacción médica
Article excerpt
Highlighted: the sentence this signal was extracted from
Roche's headquarters in Spain. Roche reinforces its commitment to the obesity drug market with a new licensing agreement with the Chinese biotech company Rona Therapeutics. The Swiss company has signed a transaction valued at up to 1.160 billion dollars (about 1.037 billion euros) to gain access to an experimental treatment targeting obesity and other metabolic diseases. The move expands its portfolio of candidates in a therapeutic area where it competes with giants like Eli Lilly and Novo Nordisk. The agreement contemplates an upfront payment of 100 million dollars and another 1.060 billion conditional upon the achievement of development, regulatory, and commercial milestones. As announced, the maximum figure announced does not constitute an immediate outlay, but rather the potential value of the transaction if the agreed conditions are met. The new license allows Roche to incorporate into its portfolio a therapeutic approach different from the drugs that have driven the recent boom in obesity treatments. Rona's candidate is based on RNA interference (RNAi) technology, which makes it possible to reduce the expression of certain genes by silencing their messenger RNA. In this case, the experimental treatment targets the ALK7 protein, which is related to the regulation of adipose tissue. The strategy seeks to act on body fat and metabolism, with the potential to reduce...
Keep reading with a free account
The rest of this article, and every signal for Roche, is in your free account.
